Compositions and methods for culturing cells from normal human tubo-ovarian epithelium and human tubo-ovarian tumors

Patent metadata

Field	Value
Publication number	US-2016319239-A1
Application number	US-201615147541-A
Country	US
Kind code	A1
Filing date	May 5, 2016
Priority date	Mar 24, 2011
Publication date	Nov 3, 2016
Grant date	—

Abstract

Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.

First claim

1 . A cell culture medium, or a kit for preparing a cell culture medium, comprising:
(a) adenosine triphosphate; (b) a carrier protein; (c) cholesterol, linoleic acid, and lipoic acid; (d) glutathione; (e) a nucleotide salvage pathway precursor base selected from hypoxanthine, xanthine, adenine, guanine and thymidine; (f) phosphoethanolamine; (g) selenium; (h) transferrin; (i) triiodothyronine; vitamin A, vitamin C, and vitamin D; (k) Zn, Mg, and Cu; (l) an agent that increases intracellular cAMP; (m) epidermal growth factor (EGF); (n) hydrocortisone; (o) insulin; and (p) serum.

2 . The cell culture medium of claim 1 , further comprising one or more of:
(a) adenosine monophosphate; (b) vitamin E; or (c) at least one of vitamin K3, niacin, or niacinamide.

3 . (canceled)

4 . The cell culture medium of claim 1 , wherein the carrier protein is albumin.

5 - 7 . (canceled)

8 . The cell culture medium of claim 1 , wherein the agent that increases intracellular cAMP is cholera toxin.

9 - 24 . (canceled)

25 . The cell culture medium of claim 1 , further comprising an estrogen.

26 - 27 . (canceled)

28 . The cell culture medium of claim 25 , wherein the estrogen is 17-beta-estradiol.

29 . The cell culture medium of claim 1 , wherein the medium is substantially free of estrogen.

30 - 36 . (canceled)

37 . The cell culture medium of claim 1 , wherein the medium supports proliferation of ovarian tumor cells for at least about 15 population doublings (PD) in vitro.

38 . The cell culture medium of claim 1 , wherein the medium supports proliferation of ovarian cells and/or fallopian tube cells for at least about 15 population doublings (PD) in vitro.

39 . A kit for preparing the cell culture medium of claim 1 , comprising a first one or more containers comprising components (a)-(k) and a second one or more containers comprising components (l)-(p) and optionally estrogen, whereby combining the contents of the first and second containers in an appropriate proportion results in the cell culture medium.

40 . A cell culture medium supplement, wherein the supplement comprises:
(a) an agent that increases intracellular cAMP; (b) epidermal growth factor (EGF); (c) hydrocortisone; (d) insulin; (e) serum; and optionally, (f) an estrogen, wherein adding the supplement to a basal cell culture medium results in the cell culture medium of claim 1 .

41 . A method of preparing the cell culture medium of claim 1 , comprising combining components (a)-(p) and optionally estrogen.

42 . (canceled)

43 . A method for culturing ovarian and fallopian tube cells, comprising:
(a) obtaining ovarian and/or fallopian tube cells from an ovary or a fallopian tube; (b) culturing the cells in the cell culture medium of claim 1 , wherein the cell culture medium supports at least 15 population doublings of the ovarian and fallopian tube epithelial cells.

44 . A method for culturing tumor cells, comprising:
(a) obtaining tumor cells; (b) culturing the tumor cells in the cell culture medium of claim 1 , wherein the cell culture medium supports at least 15 population doublings of the tumor cells.

45 - 51 . (canceled)

52 . A composition comprising
the cell culture medium of claim 1 , and cells, wherein the cells are immortalized ovarian cells and/or fallopian tube cells.

53 - 58 . (canceled)

59 . A method of identifying candidate therapeutic agents, comprising:
(a) culturing cells according to the method of claim 43 ; (b) contacting the cells with an agent; and (c) measuring one or more physiological features of the cells; wherein the agent that modulates the one or more physiological features of the cells is a candidate therapeutic agent.

60 - 65 . (canceled)

66 . A substantially purified culture of ovarian cells, wherein the ovarian cells overexpress the probesets DOK5, CD47, HS6ST3, DPP6, OSBLP3; wherein the culture comprises at least 10 3 cells; and wherein the cells are capable of undergoing at least 14 population doublings.

67 . A substantially purified culture of fallopian tube cells, wherein the fallopian tube cells overexpress the probesets STC2, SFRP1, SLC35F3, SHMT2, TMEM164; wherein the culture comprises at least 10 3 cells, and wherein the cells are capable of undergoing at least 14 population doublings.

68 - 70 . (canceled)

71 . A method of identifying candidate therapeutic agents, comprising:
(a) culturing cells according to the method of claim 44 ; (b) contacting the cells with an agent; and (c) measuring one or more physiological features of the cells; wherein the agent that modulates the one or more physiological features of the cells is a candidate therapeutic agent.

Assignees

• Whitehead Inst Biomedical Res
• Brigham & Womens Hospital Inc

Inventors

• Ince Tan A

Classifications

• C12N5/0682 Primary

  Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609) · CPC title

• G01N33/5008

  for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title

• C12N2500/20

  Transition metals · CPC title

• C12N2500/50

  Soluble polymers, e.g. polyethyleneglycol [PEG] · CPC title

• C12N2500/22

  Zinc; Zn chelators · CPC title